BioCorRx Reports Business Update for 2023
02 avr. 2024 08h30 HE
|
BioCorRx Inc
ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
[Latest] Global Water Treatment Equipment Market Size/Share Worth USD 96.7 Billion by 2032 at a 6.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
14 juil. 2023 13h30 HE
|
Custom Market Insights
Austin, TX, USA, July 14, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Water Treatment Equipment Market Size, Trends and Insights By Type (Process...
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 août 2019 16h08 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September
28 août 2019 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Announces Aggregate Gross Proceeds of $69.6 Million from $139.6 Million Public Offering and Private Placement
21 août 2019 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Announces Proposed $53.0 Million Public Offering of Preferred Stock and Warrants with Concurrent Private Placement
15 août 2019 17h37 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Operational Update
05 août 2019 16h15 HE
|
Bellicum Pharmaceuticals, Inc.
Interim safety and activity data for BPX-601 presented at American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-celTM achieved primary endpoint in BP-004 European registrational trial ...
Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial
08 juil. 2019 08h00 HE
|
Bellicum Pharmaceuticals, Inc.
Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for rivo‑cel in BP-004 European registrational trial Investigational trial results support potential that...
Getting the Dirt on Dirt for Healthier, Happier Kids
19 avr. 2012 05h00 HE
|
National Wildlife Federation
MISSION, KS--(Marketwire - Apr 19, 2012) - (Family Features) Dirt is a four-letter word to many moms, but letting your kids get dirty is actually good for them according to a new report from the...